IMMUNOTHERAPY

This study tests whether adding a drug called narlumosbart and precise radiation (SBRT) to standard chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the bones. The drug and radiation are meant to improve the immune system's ability to fi…

This study tests if taking oral sorbitol (a common sugar alcohol) can make standard chemotherapy and immunotherapy work better for people with locally advanced stomach cancer. About 80 adults will receive either sorbitol or a placebo alongside their cancer treatment. The goal is …

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to a standard treatment plan (short-course radiation, chemotherapy, and a targeted therapy) can improve outcomes for people with locally advanced rectal cancer. About 104 participants will receive the standard…

This study tests a new treatment plan for people with advanced liver cancer that has either spread to a few other spots or formed a blood clot in the main liver vein. The treatment combines chemotherapy directly into the liver artery, two immunotherapy drugs, and targeted radiati…

This study tests a two-step immunotherapy approach for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older, too frail for standard chemo, or whose cancer has returned. Participants will receive two targeted drugs in sequence: blinatumomab and inotuzumab ozogamic…

This study looks at whether a urine test for tumor DNA can help doctors decide how long to give immunotherapy to people with a severe, hard-to-treat type of bladder cancer. About 53 adults with very-high-risk non-muscle-invasive bladder cancer that cannot be fully removed by surg…

This study tests whether adding radiation therapy to a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with resectable stomach or gastroesophageal junction cancer. About 40 participants will be randomly assigned to receive either the s…

This phase 3 trial tests whether adding immunotherapy (a PD-1 inhibitor) after standard chemoradiotherapy helps adults with locally advanced esophageal squamous cell cancer live longer without the disease getting worse. About 452 participants will be randomly assigned to receive …

This study is for people with operable head and neck squamous cell carcinoma. It compares two treatment approaches given before surgery: one combines low-dose radiotherapy with targeted therapy and immunotherapy, the other uses only targeted therapy and immunotherapy. The goal is…

This study tests a combination of four drugs (iparomlimab, tuvonralimab, apatinib, and irinotecan) in 39 adults with advanced stomach cancer that produces a protein called AFP and has worsened after first-line therapy. The goal is to see if this new mix can shrink tumors or slow …

This study tests whether giving immunotherapy before surgery can help completely remove T4 colon cancers that have a genetic feature called dMMR. These cancers often don't respond to standard chemotherapy. The trial aims to see if this approach increases the chance of clean surgi…

This study tests a new treatment called RAK cell therapy for people with advanced stomach cancer that has spread or come back after standard treatments. The therapy uses immune cells from donated umbilical cord blood to help fight the cancer. The goal is to see if it can help pat…

This study tests whether adding a natural supplement (β-hydroxybutyrate) to a standard treatment plan can help shrink or eliminate rectal cancer before surgery. The plan includes short-course radiation, immunotherapy, and chemotherapy. The goal is to see if more patients achieve …

This study tests a combination of two drugs (fruquintinib and sintilimab) with or without radiation therapy for people with colorectal cancer that has spread to the liver and hasn't responded to two prior treatments. The goal is to see if this approach can control the cancer long…

This study tests whether adding a probiotic called Probio-M9 to standard chemoradiation and immunotherapy (tislelizumab) can help shrink rectal tumors before surgery. About 50 adults with locally advanced rectal cancer will be randomly assigned to receive the probiotic or a place…

This study is for people with advanced gastroesophageal junction cancer that cannot be removed with surgery. It tests a combination of targeted radiation, immunotherapy, and chemotherapy to shrink the tumor enough so that surgery becomes possible. About 88 adults will take part t…

This study tests whether adding immunotherapy to a precise type of radiation (sparing tumor-draining lymph nodes) plus chemotherapy can better control advanced esophageal cancer. About 432 adults with squamous cell carcinoma will receive either the triple combination or radiation…

This study aims to find the best treatment before surgery for esophageal cancer. It compares chemotherapy, chemoradiation, targeted therapy, and immunotherapy in 2000 adults with stage I-IVa disease. The goal is to improve survival and reduce side effects.

This study tests whether adding a probiotic supplement called Biolosion to standard chemotherapy before surgery can help more people with early-stage triple-negative breast cancer achieve a complete remission. About 192 women will be randomly assigned to receive either standard t…

This early-stage study tests an experimental drug called VSV-02 in 6 adults with advanced solid tumors (like melanoma, breast, or lung cancer) who have run out of standard options. The drug is given both into a vein and directly into the tumor to see if it can shrink or control t…

This study tests a new drug, ABT-301, combined with two existing cancer drugs (tislelizumab and bevacizumab) in people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to find the safest dose and see if the combination shrinks tu…

This large study aims to find the best combination of treatments for people with advanced esophageal or stomach junction cancer that cannot be removed by surgery. It will compare standard chemotherapy and radiation with newer approaches that add immunotherapy drugs (like PD-1/PD-…

This study is testing whether a combination of three drugs can help control recurrent ovarian cancer. It will involve about 20 adults whose cancer has returned after initial treatment. The main goals are to see if the treatment shrinks tumors and to understand what side effects p…

This study looks at whether a relaxing therapy called Reiki can help adults with cancer who feel very tired from immunotherapy. Twelve people will either get six weekly Reiki sessions right away or wait six weeks before starting. Researchers will track changes in fatigue, pain, a…

This study looks at whether a special intermittent fasting diet can help people with advanced lung cancer who are receiving immunotherapy. Researchers want to see if the diet is safe and if it can make the cancer treatment work better. About 66 patients will take part, following …

This study looks at people who finished venom immunotherapy for Jack Jumper ant allergy 1.5 to 5 years ago. Participants will get a supervised sting and blood test to see if they are still protected. The goal is to learn how long the treatment works and how it affects quality of …

This study looks at how immunotherapy for advanced cancer changes a person's physical fitness and quality of life. About 67 adults will do fitness tests and fill out questionnaires before starting treatment and again 12 weeks later. Researchers will also track their health for up…

This study looks at tiny molecules called microRNA and tumor cells floating in the blood of 300 cancer patients before and after they receive immunotherapy. The goal is to see how these markers change with treatment. This is an observational study that does not offer a new treatm…

This study is looking for a better way to predict if immunotherapy will help people with head and neck cancer. Currently, doctors use a tissue sample, but that can't be easily repeated. Researchers will test a simple blood test that looks at cancer cells and immune markers to see…

This study looks at whether a patient's emotional state—like depression or anxiety—can influence how well advanced liver cancer responds to a combination of chemotherapy, targeted therapy, and immunotherapy. Researchers will follow 90 adults with BCLC stage B or C liver cancer, d…

This study is gathering information from 500 people with small cell lung cancer to learn how to personalize treatment using radiation and immunotherapy. Researchers will track how long patients live without their cancer growing and overall survival. The goal is to find the best t…

This study collects live tumor tissue from 2,000 people with various cancers to understand why some respond to immunotherapy and others don't. Participants give a biopsy as part of their normal care, and researchers analyze the samples in the lab. The goal is to develop better wa…

This study follows 200 adults with advanced cancer who are receiving immunotherapy. Researchers will track their physical and emotional distress, financial burden, care needs, and quality of life over one year. The goal is to develop a tool that can predict who is at high risk fo…

This study watches 500 lung cancer patients who received immunotherapy before any other treatment. Researchers want to see if removing the whole lung or just part of it leads to better outcomes, and whether surgery is better than other treatments like radiation. The goal is to le…

This study looks at whether advanced blood tests and artificial intelligence can detect lung cancer coming back after surgery, earlier than standard scans. Researchers will follow 100 people who had lung cancer surgery and chemotherapy. The goal is to create a better monitoring s…